Article
[Determination of EGFR gene somatic mutations in tissues and plasma of patients with advanced non-small cell lung cancer].
Biomeditsinskaia khimiia - 1 Nov 2016
Brovkina O I, Gordiev M G, Toropovskiy A N, Khodyrev D S, Enikeev R F, Gusev O A, Shigapova L H, Nikitin A G
Abstract excerpt
The presence of activating mutations in the EGFR gene influences cell proliferation, angiogenesis, and increases metastatic ability; it has a significant impact on the choice of medical therapy of non-small cell lung cancer (NSCLC). The use of targeted therapy with tyrosine kinase inhibitors requires performance of appropriate genetic tests. The aim of this study was to design a real-time PCR-based diagnostic kit...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
